MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid t… Read more
MorphoSys AG (MPSYF) - Total Liabilities
Latest total liabilities as of March 2024: $2.09 Billion USD
Based on the latest financial reports, MorphoSys AG (MPSYF) has total liabilities worth $2.09 Billion USD as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MorphoSys AG - Total Liabilities Trend (2002–2023)
This chart illustrates how MorphoSys AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MorphoSys AG Competitors by Total Liabilities
The table below lists competitors of MorphoSys AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
APEX Wind Power Equipment Manufacturing
TWO:7702
|
Taiwan | NT$1.12 Billion |
|
Tasco Bhd
KLSE:5140
|
Malaysia | RM1.40 Billion |
|
Lii Hen Industries Bhd
KLSE:7089
|
Malaysia | RM104.70 Million |
|
Anxo Pharmaceutical Co., Ltd.
TWO:6677
|
Taiwan | NT$931.96 Million |
Liability Composition Analysis (2002–2023)
This chart breaks down MorphoSys AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MorphoSys AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MorphoSys AG (2002–2023)
The table below shows the annual total liabilities of MorphoSys AG from 2002 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $1.98 Billion | -11.71% |
| 2022-12-31 | $2.24 Billion | -3.11% |
| 2021-12-31 | $2.31 Billion | +122.64% |
| 2020-12-31 | $1.04 Billion | +920.46% |
| 2019-12-31 | $101.74 Million | +101.90% |
| 2018-12-31 | $50.39 Million | -11.17% |
| 2017-12-31 | $56.73 Million | +17.84% |
| 2016-12-31 | $48.14 Million | +28.91% |
| 2015-12-31 | $37.34 Million | -51.92% |
| 2014-12-31 | $77.67 Million | -18.67% |
| 2013-12-31 | $95.51 Million | +328.71% |
| 2012-12-31 | $22.28 Million | -28.76% |
| 2011-12-31 | $31.27 Million | +17.43% |
| 2010-12-31 | $26.63 Million | -17.18% |
| 2009-12-31 | $32.16 Million | -22.15% |
| 2008-12-31 | $41.31 Million | +5.44% |
| 2007-12-31 | $39.18 Million | +40.96% |
| 2006-12-31 | $27.79 Million | +72.53% |
| 2005-12-31 | $16.11 Million | -1.88% |
| 2004-12-31 | $16.42 Million | +5.40% |
| 2003-12-31 | $15.58 Million | -28.48% |
| 2002-12-31 | $21.78 Million | -- |